Navigation Links
Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development
Date:10/5/2009

SEATTLE, Oct. 5 /PRNewswire-FirstCall/ -- Isilon® Systems (Nasdaq: ISLN), the proven leader in scale-out NAS, today announced that Pharmacogenomics Centre, a partnership between Genome Quebec and the Montreal Heart Institute focused on enhancing new and existing drug development research programs through the inclusion of genetic information, has deployed Isilon IQ to accelerate its next-generation genetic sequencing operations. In its focused efforts to fight heart disease, cancer and other life-threatening diseases, Pharmacogenomics Centre is leveraging Isilon scale-out NAS to significantly increase workflow efficiency and productivity, while reducing storage management from more than 30 hours per week to less than one hour per week.

"We're sequencing targeted segments of patients' DNA to try and identify individual mutations that can cause those patients to respond unexpectedly to specific drug therapies," said Christopher Beck, senior bioinformatician, Pharmacogenomics Centre. "Obviously the data produced by our next-generation sequencers is mission-critical but we are a scientific organization and our main focus is data analysis, not data storage. We simply can't afford the lengthy storage deployment schedules or complex system management hassles that traditional storage offerings require. With Isilon, we've been able to deploy and manage a high-performance, highly scalable, shared storage resource without having to dedicate any IT staff to managing the system."

With Isilon scale-out NAS, Pharmacogenomics Centre has unified both its DNA sequencing and DNA analysis operations onto a single, shared pool of storage, enabling highly concurrent processing of genomic data to increase productivity and speed time-to-results. Additionally, with Isilon's OneFS® operating system providing 'pay as you grow' scalability, Pharmacogenomics Centre can scale both performance and capacity on-demand to meet the dramatic and unpredictable growth of data within its high-throughput sequencing environment.

"Next-generation genetics research is opening entirely new ways of undertaking critical drug discovery research," said Chris Blessington, senior director of marketing and communications, Isilon Systems. "Pharamcogenomics Centre's successful use of Isilon IQ to advance this new era of drug development is demonstrative of the inherent performance, capacity, and manageability advantages of our scale-out NAS solutions for data-rich life sciences organizations."

About Isilon Systems

Isilon Systems (Nasdaq: ISLN) is the proven leader in scale-out NAS. Isilon's clustered storage and data management solutions drive unique business value for customers by maximizing the performance of their mission-critical applications, workflows, and processes. Isilon enables enterprises and research organizations worldwide to manage large and rapidly growing amounts of file-based data in a highly scalable, easy-to-manage, and cost-effective way. Information about Isilon can be found at http://www.isilon.com.

The names of companies mentioned herein are the trademarks of their respective owners.

SOURCE Isilon Systems


'/>"/>
SOURCE Isilon Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
2. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
3. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
4. First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology
5. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
6. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
7. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
8. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
9. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
10. Breakthrough Mapping of Alzheimers Genome Helps ID Four New Suspect Genes
11. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):